MARKET

BIXT

BIXT

Bioxytran Inc
OTCMQB
0.050
+0.003
+6.85%
Closed 13:35 02/18 EST
OPEN
0.050
PREV CLOSE
0.047
HIGH
0.050
LOW
0.050
VOLUME
30.00K
TURNOVER
1.50K
52 WEEK HIGH
0.220
52 WEEK LOW
0.037
MARKET CAP
4.95M
P/E (TTM)
-2.1234
1D
5D
1M
3M
1Y
5Y
1D
Bioxytran Signs Distribution Deal, Initiates Commercial Nutraceutical Shift
TipRanks · 1d ago
Weekly Report: what happened at BIXT last week (0209-0213)?
Weekly Report · 2d ago
Bioxytran Reports Strong Phase 2 Results for ProLectin-M
TipRanks · 02/11 11:30
BRIEF-Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance With Prolectin-Mbioxytran
Reuters · 02/11 11:01
Bioxytran Reports 100% Viral Clearance in Phase 2 Trial of ProLectin-M
Reuters · 02/11 11:00
BIOXYTRAN REPORTS POSITIVE PHASE 2 RESULTS DEMONSTRATING RAPID VIRAL CLEARANCE WITH PROLECTIN-MBIOXYTRAN
Reuters · 02/11 11:00
Weekly Report: what happened at BIXT last week (0202-0206)?
Weekly Report · 02/09 09:53
Bioxytran CEO to Present at Noble Capital Markets' Emerging Growth Virtual Equity Conference
Reuters · 02/04 21:26
More
About BIXT
Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

Webull offers Bioxytran Inc stock information, including OTCMQB: BIXT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIXT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIXT stock methods without spending real money on the virtual paper trading platform.